An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip
Key Points
The disposition involved 21,500 shares valued at about $605,000 as of the August 14 transaction date.
Soleil Boughton maintains direct ownership of 339,000 shares and holds additional derivative securities following the liquidation.
The activity was non-discretionary and executed to cover tax obligations, indicating no shift in the insider's investment thesis.
Soleil Boughton, the chief legal officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a non-discretionary disposition of 21,500 shares on August 14, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$605,000 |
| Shares sold | 21,500 |
| Post-transaction shares (directly held) | 339,075 |
| Post-transaction value | ~$9.5 million |
Transaction value based on SEC Form 4 weighted average sale price ($28.15); post-transaction value based on the August 14 market close ($28.15).
Key questions
- What initiated this disposition of Class A Common Stock?
The transaction was a non-discretionary move executed to satisfy tax withholding requirements tied to the vesting and settlement of restricted stock units. - Does this transaction reflect a shift in the insider's assessment of the company?
No, the sale was part of a pre-arranged tax withholding process and does not reflect an active assessment of the company's valuation or future prospects. - What is the extent of the insider's remaining equity exposure?
Boughton retains 339,075 shares in direct ownership and also holds additional derivative securities, including both vested and unvested awards. - What was the stock's performance context on the transaction date?
The disposition occurred after a one-year return of -40% as of August 14, with the shares priced at $28.15 per share.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-17) | $28.61 |
| Market Capitalization | $6.4 billion |
| Revenue (TTM) | $2.6 billion |
| Net Income (TTM) | -$142.0 million |
Company Snapshot
- Hims & Hers operates a comprehensive digital health platform that delivers prescription medications, over-the-counter drugs, medical devices, cosmetics, and dietary supplements directly to consumers through its websites and mobile application.
- The company generates revenue through a direct-to-consumer model by connecting patients with licensed medical professionals for virtual consultations and facilitating the sale of health and wellness products with recurring subscription and transaction-based revenue streams.
- The company primarily serves consumers seeking convenient, accessible healthcare solutions and wellness products, targeting individuals who prefer digital-first medical consultations and home delivery of pharmaceutical and consumer health products.
Hims & Hers Health operates as a leading digital health platform with a $6.4 billion market capitalization and $2.6 billion in TTM revenue, positioning itself at the intersection of telehealth and direct-to-consumer pharmaceutical distribution. The company's integrated platform model creates competitive advantages through operational efficiency, customer convenience, and data-driven personalization. Despite current net losses of $142.0 million TTM, the company's substantial revenue base and market scale reflect strong consumer adoption of its digital-first healthcare delivery model.
What this transaction means for investors
As chief legal officer, Boughton oversees a key fight that's shaping HIMS stock. The FTC sued the company on July 29 over data sharing and billing practices, and that lawsuit is already showing up on the income statement as a $47.5 million legal contingency in the second quarter. In a statement, the company called the suit an attempt to "generate headlines at our expense,” and the firm's CFO on the latest earnings call said HIMS is "not prepared to accept the terms we do not believe reflect the facts or the law," so investors shouldn't expect a quick settlement.
However, if you set the legal overhang aside, the underlying business is doing fine. Revenue grew 38% last quarter to $753.2 million, and management raised full-year guidance to $3.1 billion to $3.3 billion. The real tension for a buyer isn't insider selling, it's whether that growth is worth paying for while a federal regulator is actively litigating how the company gets its customers. That could be a bet on the lawsuit's outcome as much as one on the business itself.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.